Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz4. fázis

Beta-lactam Intermittent Versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis

A legfontosabb adatok

Ki végzi
Assistance Publique - Hôpitaux de Paris
Hol
Franciaország23 helyszín, 1 országbanVálassz országot a helyszínekhez
Állapot
Fut, nem toboroz
Fázis
4. fázis
Résztvevők
600 fő, tervezett
Kezdés
2023. nov. 13.
Várható befejezés
2027. márc. 4.
A vizsgálat típusa
Beavatkozással járó, 4 csoport
A vizsgált kezelések
  • continuous pivotal βL-AB
  • intermittent pivotal βL-AB
  • AG infusion most 1 dose
  • AG infusion for 5 days
A regiszteradat frissítve
2026. október 16.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 22 feltétel megnézéseKevesebb

Ki vehet részt

  • Adults (≥ 18 years)
  • Hospital-acquired sepsis (according to sepsis 3.0 definitions) :; Patient hospitalized for more than 48 hours OR Patient discharged less than 48 hours ago; AND sepsis diagnosed within the last 24 hours
  • One of the following risk factors for gram negative multidrug resistant pathogens:; Prior intravenous antibiotic use within 7 days prior to sepsis onset with the exception of antibiotic effective only against Gram-positive bacteria, penicillin A and macrolides; Prolonged hospital stay (≥ 15 days of hospitalization) within 3 months prior to sepsis onset Prolonged mechanical ventilation (≥ 5 days on mechanical ventilation) within 3 months prior to sepsis onset; Patients with indwelling devices (dialysis access lines, intravascular lines, urinary catheter, endotracheal or tracheostomy tube, gastrostomy or jejunostomy feeding tube); Patients known to be infected, colonized or carriers of MDR gram negative bacteria within 3 months prior to sepsis onset; Exposure to an antibiotic (amoxicillin-clavulanic acid, C2G, C3G, fluoroquinolones) within 3 months prior to sepsis onset; A trip abroad to known geographical areas at risk (in particular the Indian subcontinent, South-East Asia, the Middle East and North Africa, the Mediterranean Basin) within 3 months prior to sepsis onset; A functional or organic abnormality of the urinary tract in case of urinary tract infection
  • Appropriate bacteriological sampling performed before starting antimicrobial therapy
  • Expected stay in ICU of more than 3 days

Ki nem vehet részt

  • Bone marrow transplant or chemotherapy-induced neutropenia
  • Enrolment to another interventional drug study
  • Known hypersensitivity to ceftazidime, piperacillin-tazobactam, cefepime, meropenem, ceftazidime-avibactam, ceftazolane-avibactam or to any of the excipients included in the corresponding pharmaceutical drugs,
  • Known hypersensitivity to any cephalosporin antibacterial agent,
  • Severe known hypersensitivity (eg, anaphylactic reaction, severe skin reaction) to any other beta-lactam antibiotic (eg, penicillins or monobactam ) or to any of its excipients
  • Known contraindication to the aminoglycoside family including; Hypersensitivity to the active substance, to any aminoglycoside antibacterial agent or to any of the excipients included in the corresponding pharmaceutical drugs,; Cirrhosis of grades B and C according to the Child-Pugh classification; Myasthenia gravis; Simultaneous administration of another aminoglycoside; Association with ataluren
  • Non-complicated urinary tract infection (corresponding to a positive ECBU not responsible for sepsis)
  • Infections for which long-term antibiotic treatment > 8 days is strongly recommended (i.e., infective endocarditis, osteoarticular infections, anterior mediastinitis after cardiac surgery, hepatic or cerebral abscesses, chronic prostatitis for instance
  • A priori known resistance to all the proposed beta-lactams or to amikacin
  • Need for extrarenal treatment at inclusion according to the criteria of Gaudry et al
  • Know hypersentitivity to any penem antibacterial agent,
  • Presence of antibiotic therapyfor the new sepsis before randomisation: (> 2 doses of antibiotics or > 16h for continuous infusion
  • Limitation of life support (comfort care applied only) at the time of screening
  • Pregnancy or breastfeeding
  • Subject deprived of freedom, subject under a legal protective measure
  • Non affiliation to any health insurance system
  • Refusal to participate to the study (patient or legal representative or family member or close relative if present)

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Patients hospitalized in ICU with sepsis (infection with life-threatening organ dysfunction according to sepsis 3.0 definitions) or septic shock presumably due to MDR-GNB (multidrug resistant Gram-negative bacteria). The study will be a prospective multicentre, randomized, open-label comparative continuous vs. intermittent pivotal βL (Beta Lactamine) antibiotic infusion strategies and combination vs. monotherapy trial conducted with a 2X2 factorial design.

A vizsgálat 4 csoportja

  • continuous infusion dosing of a pivotal AND AG infusion for 5 daysA vizsgált kezelés

    continuous infusion dosing of a pivotal βL-AB (CID group) AND AG infusion for 5 days (long duration) as appropriate combination therapy (ACT group)

    Kezelés: continuous pivotal βL-AB és AG infusion for 5 days

  • intermittent infusion dosing of a pivotal βL-AB ND AG infusion for 5 daysA vizsgált kezelés

    intermittent infusion dosing of a pivotal βL-AB (IID = control group) AND AG infusion for 5 days (long duration) as appropriate combination therapy (ACT = group)

    Kezelés: intermittent pivotal βL-AB és AG infusion for 5 days

  • continuous infusion dosing of a pivotal βL-AB AND AG infusion at most 1 doseA vizsgált kezelés

    continuous infusion dosing of a pivotal βL-AB (CID group) AND AG infusion at most 1 dose (AMT group )

    Kezelés: continuous pivotal βL-AB és AG infusion most 1 dose

  • intermittent infusion dosing of a pivotal βL-AB AND AG infusion at most 1 doseA vizsgált kezelés

    intermittent infusion dosing of a pivotal βL-AB (IID = group) AND AG infusion at most 1 dose (AMT group)

    Kezelés: intermittent pivotal βL-AB és AG infusion most 1 dose

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
A regiszteradat frissítve
2026. október 16.